MA44253A - Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1 - Google Patents
Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1Info
- Publication number
- MA44253A MA44253A MA044253A MA44253A MA44253A MA 44253 A MA44253 A MA 44253A MA 044253 A MA044253 A MA 044253A MA 44253 A MA44253 A MA 44253A MA 44253 A MA44253 A MA 44253A
- Authority
- MA
- Morocco
- Prior art keywords
- acetylcholin
- muscarinic
- receptor
- positive allosteric
- allosteric modulators
- Prior art date
Links
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 title 1
- 230000003551 muscarinic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662296012P | 2016-02-16 | 2016-02-16 | |
| US201662402438P | 2016-09-30 | 2016-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44253A true MA44253A (fr) | 2018-12-26 |
Family
ID=59626207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044253A MA44253A (fr) | 2016-02-16 | 2017-02-16 | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11111251B2 (enExample) |
| EP (1) | EP3416639B1 (enExample) |
| JP (1) | JP2019504901A (enExample) |
| KR (1) | KR20180110132A (enExample) |
| CN (1) | CN109069491A (enExample) |
| AU (1) | AU2017221404A1 (enExample) |
| BR (1) | BR112018016689A2 (enExample) |
| CA (1) | CA3014791A1 (enExample) |
| CL (1) | CL2018002335A1 (enExample) |
| EA (1) | EA201891854A1 (enExample) |
| IL (1) | IL261058A (enExample) |
| MA (1) | MA44253A (enExample) |
| MX (1) | MX385975B (enExample) |
| PH (1) | PH12018501731A1 (enExample) |
| WO (1) | WO2017143041A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2824495T3 (es) * | 2016-09-02 | 2021-05-12 | Suven Life Sciences Ltd | Moduladores alostéricos positivos del receptor muscarínico M1 |
| EA035599B1 (ru) * | 2017-04-13 | 2020-07-14 | Сувен Лайф Сайенсиз Лимитед | Позитивные аллостерические модуляторы мускариновых m1-рецепторов |
| AU2018289939B2 (en) * | 2017-06-20 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| PT3643718T (pt) | 2017-06-20 | 2023-10-26 | Takeda Pharmaceuticals Co | Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1 |
| CN111491920B (zh) * | 2017-10-20 | 2024-01-30 | 范德比尔特大学 | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 |
| CN111278814B (zh) * | 2017-10-27 | 2022-10-28 | 苏文生命科学有限公司 | 作为毒蕈碱m1受体正向别构调节剂的多环酰胺 |
| US11352344B2 (en) | 2017-10-31 | 2022-06-07 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| CA3090130A1 (en) | 2018-02-02 | 2019-08-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| US11851406B2 (en) * | 2018-06-13 | 2023-12-26 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
| JP7443238B2 (ja) | 2018-09-28 | 2024-03-05 | 武田薬品工業株式会社 | 複素環化合物 |
| JP7446232B2 (ja) | 2018-09-28 | 2024-03-08 | 武田薬品工業株式会社 | 縮合環化合物 |
| EP3643711A1 (en) * | 2018-10-24 | 2020-04-29 | Bayer Animal Health GmbH | New anthelmintic compounds |
| US12065433B2 (en) | 2018-10-24 | 2024-08-20 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
| CA3155864A1 (en) | 2019-10-04 | 2021-04-08 | Vanderbilt University | MUSCARINIC ACETYLCHOLINE M4 RECEPTOR ANTAGONISTS |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4608079A (en) | 1983-08-02 | 1986-08-26 | American Cyanamid Company | Imidazolidinones, and imidazolidinethiones, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents |
| DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| AU759875B2 (en) | 1999-03-09 | 2003-05-01 | Pharmacia & Upjohn Company | 4-OXO-4,7-dihydro-thieno(2,3-b)pyridine-5-carboxamides as antiviral agents |
| CN1814596A (zh) | 2000-04-28 | 2006-08-09 | 阿卡蒂亚药品公司 | 毒蕈碱性激动剂 |
| EA007429B1 (ru) * | 2001-10-02 | 2006-10-27 | Фармация Энд Апджон Компани | Азабициклические замещённые конденсированные гетероарильные соединения |
| EA022494B1 (ru) * | 2009-12-17 | 2016-01-29 | Мерк Шарп Энд Домэ Корп. | Соединения хинолинамида в качестве положительных аллостерических модуляторов мускаринового рецептора m1 |
| US8815902B2 (en) | 2010-06-15 | 2014-08-26 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide M1 receptor positive allosteric modulators |
| WO2012158474A1 (en) * | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-linked quinolineamide m1 receptor positive allosteric modulators |
| WO2015027204A1 (en) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| TW201512197A (zh) | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| CA2930961A1 (en) | 2014-01-22 | 2015-07-30 | F. Hoffmann-La Roche Ag | Fluoro-naphthyl derivatives |
| US10214508B2 (en) | 2014-06-13 | 2019-02-26 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| WO2016009297A1 (en) * | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
| WO2016029454A1 (en) | 2014-08-29 | 2016-03-03 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
| ES2824495T3 (es) | 2016-09-02 | 2021-05-12 | Suven Life Sciences Ltd | Moduladores alostéricos positivos del receptor muscarínico M1 |
-
2017
- 2017-02-16 EP EP17753822.0A patent/EP3416639B1/en active Active
- 2017-02-16 KR KR1020187026643A patent/KR20180110132A/ko not_active Withdrawn
- 2017-02-16 US US15/998,899 patent/US11111251B2/en active Active
- 2017-02-16 BR BR112018016689A patent/BR112018016689A2/pt not_active IP Right Cessation
- 2017-02-16 JP JP2018561928A patent/JP2019504901A/ja active Pending
- 2017-02-16 MX MX2018009952A patent/MX385975B/es unknown
- 2017-02-16 WO PCT/US2017/018140 patent/WO2017143041A1/en not_active Ceased
- 2017-02-16 MA MA044253A patent/MA44253A/fr unknown
- 2017-02-16 AU AU2017221404A patent/AU2017221404A1/en not_active Abandoned
- 2017-02-16 CA CA3014791A patent/CA3014791A1/en active Pending
- 2017-02-16 CN CN201780023438.3A patent/CN109069491A/zh active Pending
- 2017-02-16 EA EA201891854A patent/EA201891854A1/ru unknown
-
2018
- 2018-08-08 IL IL261058A patent/IL261058A/en unknown
- 2018-08-14 CL CL2018002335A patent/CL2018002335A1/es unknown
- 2018-08-15 PH PH12018501731A patent/PH12018501731A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL261058A (en) | 2018-10-31 |
| BR112018016689A2 (pt) | 2019-02-12 |
| EA201891854A1 (ru) | 2019-01-31 |
| US20210230180A1 (en) | 2021-07-29 |
| JP2019504901A (ja) | 2019-02-21 |
| CA3014791A1 (en) | 2017-08-24 |
| AU2017221404A1 (en) | 2018-08-23 |
| CL2018002335A1 (es) | 2019-02-01 |
| MX385975B (es) | 2025-03-18 |
| EP3416639A4 (en) | 2019-07-03 |
| EP3416639B1 (en) | 2022-06-08 |
| CN109069491A (zh) | 2018-12-21 |
| MX2018009952A (es) | 2018-11-29 |
| PH12018501731A1 (en) | 2019-06-17 |
| EP3416639A1 (en) | 2018-12-26 |
| US11111251B2 (en) | 2021-09-07 |
| WO2017143041A1 (en) | 2017-08-24 |
| KR20180110132A (ko) | 2018-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45463A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
| MA44253A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1 | |
| HUE053586T2 (hu) | Muszkarin M1 receptor pozitív alloszterikus modulátorok | |
| DK3452448T3 (da) | Modulatorer af den integrerede stressvej | |
| MA47127A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
| MA43756A (fr) | Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine | |
| MA46722A (fr) | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 | |
| MA46899A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
| EP3558306A4 (en) | ALLOSTERIC 6.5-CONDENSED HETEROARYL PIPERIDINE ETHER MODULATORS OF THE M4 MUSCARINIC ACETYL CHOLINE RECEPTOR | |
| MA47126A (fr) | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 | |
| BR112017026561A2 (pt) | moduladores alostéricos positivos do receptor muscarínico m2 | |
| IL255994A (en) | Muscarinic receptor modulators if 1. positive allosteric | |
| MA50464A (fr) | Amides polycycliques utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
| EP3534888A4 (en) | SUBSTITUTED BICYCLIC HETEROARYL-ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | |
| SI3248964T1 (sl) | Tiazolovi modulatorji A3 adenozinskega receptorja | |
| MA51036A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
| MA51037A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
| MA50806A (fr) | Azacycles substitués utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
| HK40002190A (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 | |
| HK40015440A (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| HK40015439A (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| UA36196S (uk) | Тяга верхня навісного пристрою транспортного засобу |